Next Generation Modalities in Drug Discovery & Development
BIOL-40394
Participants will delve into the science and technology behind novel therapeutic approaches such as gene therapy, RNA-based therapies, cell-based treatments, and biologics including monoclonal antibodies and biosimilars. The course will cover the principles of designing, developing, and evaluating these innovative therapies, emphasizing the regulatory and clinical challenges associated with their development. Through a combination of theoretical lectures, case studies, and interactive discussions, students will gain a comprehensive understanding of how these new modalities are integrated into the drug development pipeline, from initial discovery to market approval. This course is ideal for professionals in pharmaceutical and biotech industries, researchers, and regulatory affairs specialists looking to stay at the forefront of therapeutic innovation.
Course Information
Course sessions
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 10/20/2025
Schedule:
Instructor:
David Briere
David Briere earned his Bachelor of Arts in Psychology and a Biotechnical Certificate from the University of Wisconsin-Milwaukee and Oshkosh. He then pursued his Master of Science in Neuroscience at the University of Hartford in Connecticut.
He began his scientific career as a cancer biologist with Pfizer Inc. in Groton, CT, where he met his wife and started their family. They now have a 13-year-old daughter. Over the next decade, he worked at Pfizer (relocating to San Diego in 2007) and Takeda Pharmaceuticals, taking on increasing responsibilities in generating impactful data sets to transition preclinical projects into approved medicines.
In December 2013, David joined Mirati Therapeutics Inc. as its first scientist. Over the past 11 years, he has played a crucial role in the company's evolution from a start-up to a multi-billion-dollar pharmaceutical company, which was acquired by Bristol-Myers Squibb Inc. in 2023. His contributions include the discovery and development of Krazati (adagrasib), an approved agent that has extended the lives of thousands of lung cancer patients.
David is still excited about making new treatments for cancer. He finds it more rewarding to share his experiences and help the next generation of scientists. His dedication to both research and education continues to drive his professional endeavors.